Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
12,214
archived clinical trials in
Women's Studies

Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
RTI International
mi
from
Durham, NC
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
RTI International
mi
from
Durham, NC
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
The Research Institute at Nationwide Children's Hospital
mi
from
Columbus, OH
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
The Research Institute at Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Univeristy of Pennsylvania
mi
from
Philadelphia, PA
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Univeristy of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Brown University, Women & Infants Hospital of Rhode Island
mi
from
Providence, RI
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
UT Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Stanford University
mi
from
Palo Alto, CA
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Medical Center
mi
from
Cincinnati, OH
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated:  12/31/1969
Case Western Reserve University, Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Inositol to Reduce Retinopathy of Prematurity
INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants
Status: Enrolling
Updated: 12/31/1969
Case Western Reserve University, Rainbow Babies and Children's Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
The Utility of Pretracheal Stethoscope in Detecting Respiratory Abnormalities in Sedated Children
The Utility of Amplified Pretracheal Stethoscope in Detecting Ventilatory Abnormalities During Propofol Sedation of Non Intubated Children: a Validation Study
Status: Enrolling
Updated:  12/31/1969
American Family Children's Hospital (AFCH)
mi
from
Madison, WI
The Utility of Pretracheal Stethoscope in Detecting Respiratory Abnormalities in Sedated Children
The Utility of Amplified Pretracheal Stethoscope in Detecting Ventilatory Abnormalities During Propofol Sedation of Non Intubated Children: a Validation Study
Status: Enrolling
Updated: 12/31/1969
American Family Children's Hospital (AFCH)
mi
from
Madison, WI
Click here to add this to my saved trials
GSK1120212+GSK2141795 for Cervical Cancer
A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
GSK1120212+GSK2141795 for Cervical Cancer
A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated:  12/31/1969
Banner Good Samaritan Regional Medical Center
mi
from
Phoenix, AZ
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated: 12/31/1969
Banner Good Samaritan Regional Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated:  12/31/1969
Christiana Care Health System CCHS
mi
from
Newark, DE
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated: 12/31/1969
Christiana Care Health System CCHS
mi
from
Newark, DE
Click here to add this to my saved trials
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated:  12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated: 12/31/1969
Lehigh Valley Hospital
mi
from
Allentown, PA
Click here to add this to my saved trials
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated:  12/31/1969
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
FOLCROM Trial: Foley Catheter in Rupture of Membranes
Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)
Status: Enrolling
Updated: 12/31/1969
Geisinger Wyoming Valley Medical Center
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center - Basking Ridge
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Center @ Suffolk
mi
from
Commack, NY
Click here to add this to my saved trials
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center at Mercy Medical Center
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Monmouth
mi
from
Middletown, NJ
Click here to add this to my saved trials
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Westchester
mi
from
Harrison, NY
Click here to add this to my saved trials
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New York, NY
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Charlottesville, VA
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women
Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania, Penn Center for Womens Behavioral Wellness
mi
from
Philadelphia, PA
LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women
Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania, Penn Center for Womens Behavioral Wellness
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
University Hospital
mi
from
Newark, NJ
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
University Hospital
mi
from
Newark, NJ
Click here to add this to my saved trials
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Garden State Urology
mi
from
Whippany, NJ
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Garden State Urology
mi
from
Whippany, NJ
Click here to add this to my saved trials
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated:  12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer
Status: Enrolling
Updated: 12/31/1969
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography
What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography
Status: Enrolling
Updated:  12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography
What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography
Status: Enrolling
Updated: 12/31/1969
University of Michigan Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
BABY STEPS II: SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit
SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
BABY STEPS II: SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit
SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
University of South Alabama Medical Center
mi
from
Mobile, AL
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
University of South Alabama Medical Center
mi
from
Mobile, AL
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Good Samaritan Hospital
mi
from
San Jose, CA
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Good Samaritan Hospital
mi
from
San Jose, CA
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Presbyterian/St Luke's Hospital
mi
from
Denver, CO
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Presbyterian/St Luke's Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Denver Health and Hospital Authority
mi
from
Denver, CO
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Denver Health and Hospital Authority
mi
from
Denver, CO
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Norton Kosair Children's Hospital
mi
from
Louisville, KY
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Norton Kosair Children's Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Tulane - Lakeside Hospital for Women and Children
mi
from
Metairie, LA
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Tulane - Lakeside Hospital for Women and Children
mi
from
Metairie, LA
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Touro Infirmary
mi
from
New Orleans, LA
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Touro Infirmary
mi
from
New Orleans, LA
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated:  12/31/1969
Baylor/Texas Children's Hospital & Pavilion
mi
from
Houston, TX
Vaginal Pessary Versus Expectant Management for Placenta Previa
Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa
Status: Enrolling
Updated: 12/31/1969
Baylor/Texas Children's Hospital & Pavilion
mi
from
Houston, TX
Click here to add this to my saved trials